Chief Editor
James D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis, Insmed and Trudell; and received consultancy or speaker fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer, Trudell and Zambon.
Deputy Chief Editor
Don D. Sin has received a stipend for giving talks on COPD from AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim.
Section Editors
Stefano Aliberti has received research grants from Insmed, Chiesi, Takeda and Fisher & Paykel, and received consultancy or speaker fees from GSK, Insmed, Zambon, AstraZeneca, CSL Behring GmbH, Menarini and MSD Italy.
Isabella Annesi-Maesano has no potential conflicts of interest to disclose.
Mona Bafadhel has received grants (paid to institution) from AstraZeneca, Roche and Asthma+Lung UK, received consultancy or speaker fees paid to institution from AstraZeneca, Chiesi, GlaxoSmithKline and Sanofi, and has been a scientific advisor to ProAxsis and AlbusHealth.
Marc Humbert has received grants or contracts from AOP Orphan, Janssen, Merck and Shou Ti, and provided consultancy for Aerovate, Altavant, AOP Orphan, AstraZeneca, Bayer, Chiesi, Ferrer, GlaxoSmithKline, Janssen, Morphogen IX, Sanofi, Shou Ti and United Therapeutics.
Martin Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape.
Claudia Kuehni has no potential conflicts of interest to disclose.
Patrick Lévy has received consultancy fees from KeepMed, Agiradom and BioSerenity, and has also been consultant for Mosanna.
Giovanni Battista Migliori has no potential conflicts of interest to disclose.
Paul M. O’Byrne is a member of the Joint Oversight Board for LABA Safety Study, has received consultancy fees from AstraZeneca, GSK, Chiesi and Covis, and has received grants from AstraZeneca, Genentech, Novartis, Merck and Biohaven.
Francesca Polverino has received unrestricted research funding from Boehringer Ingelheim, and funding from the NIH/NHLBI, is a standing member of the Flanders Research Foundation study section, and executive board member of the American Thoracic Society RCMB assembly.
José M. Porcel has received consultancy fees from Cogora/Becton Dickinson.
Associate Editors
Esther Barreiro has no potential conflicts of interest to disclose.
Chloe I. Bloom has no potential conflicts of interest to disclose.
Pierre-Régis Burgel reports grants from Boehringer Ingelheim, GSK and Vertex, payment or honoraria for consultancy, lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, GSK, AstraZeneca, Vertex, Chiesi, Pfizer, Novartis, Zambon and Insmed, and support for attending meetings and/or travel from AstraZeneca and Chiesi.
Vincent Cottin reports grants from Boehringer Ingelheim, consultancy fees from Boehringer Ingelheim, Roche, Shionogi, RedX, Pure Tech, Celgene/BMS, AstraZeneca, CSL Behring, Sanofi, United Therapeutics/Ferrer and Pliant, payment or honoraria for lectures from Boehringer Ingelheim and Roche, support for attending meetings from Boehringer Ingelheim and Roche, and participation on a data safety monitoring board or advisory board for Galapagos and Galecto.
Bruno Crestani has received personal fees and non-financial support from AstraZeneca, Apelis and Sanofi, grants, personal fees and non-financial support from Boehringer Ingelheim, non-financial support from Cardif and lvl, and grants from MedImmune.
Anh Tuan Dinh-Xuan has received consultancy and/or speaker’s fees from Air Liquide Santé, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK and Novartis.
David Gozal has no potential conflicts of interest to disclose.
Christophe Guignabert has received grants and personal fees from Merck, and grants from Acceleron, Structure Therapeutics (ex-ShouTi), Janssen and Corteria Pharmaceuticals.
Sergio Harari has relationships with drug companies including Roche, Actelion and Boehringer Ingelheim. In addition to being investigator in trials involving these companies, relationships include fees for lectures and membership of scientific advisory boards, and grants for research.
Paul Hassoun is on the advisory board of ARIA SAB and serves on a scientific steering committee for Merck & Co., Inc.
Pieter S. Hiemstra has received research grants from Boehringer Ingelheim and Galapagos N.V.; and has served on an Advisory Board for GSK. These grants, reimbursements and fees were paid to the institution.
Marius M. Hoeper has received honoraria for lectures and/or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, Gossamer Bio and Janssen.
John R. Hurst has no potential conflicts of interest to disclose.
Yet Hong Khor has no potential conflicts of interest to disclose.
Melanie Koenigshoff has no potential conflicts of interest to disclose.
Stavros Konstantinides has received fees for consultancy and lecture honoraria from Bayer HealthCare, Boehringer Ingelheim, Actelion, Servier and BMS Pfizer; reimbursement for travel, accommodation and meeting expenses from Bayer HealthCare; and institutional grants from Boehringer Ingelheim, Bayer HealthCare, Daiichi Sankyo and Actelion.
Tom Kotsimbos has received investigator-initiated study support and clinical trial support from Vertex P/L.
Wolfgang Kübler has no potential conflicts of interest to disclose.
Marcus A. Mall has received personal fees from Abbvie, Antabio, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Pari, Pieris Pharmaceuticals, Santhera, Sterna Biologicals and Vertex Pharmaceuticals for consultancy services, lectures and membership of scientific advisory boards related to the development of novel therapies for cystic fibrosis.
Silke Meiners has no potential conflicts of interest to disclose.
Martin R. Miller has no potential conflicts of interest to disclose.
Catherine W.M. Ong has received speaking fees from Qiagen, and research grants from Institut Meriuex and National Medical Research Council, Singapore.
Hye Yun Park has no potential conflicts of interest to disclose.
Laura C. Price has no potential conflicts of interest to disclose.
Ganesh Raghu has provided consultation services to Avalyn, Boehringer Ingelheim, Bellerophan, BMS, Biogen, Blade Therapeutics, Fibrogen, Humanetics, Promedior, Nitto, Respivant, Roche-Genentech, Veracyte and Zambon, and has received research grant support from the National Institutes of Health, Bethesda, MD, USA.
Marcos I. Restrepo has no potential conflicts of interest to disclose.
Renata L. Riha received fees for consultancy from JAZZ Pharma in 2020, but has no ongoing consultancies or other conflicts of interest.
Thomas Similowski reports personal fees from ADEP Assitance, AstraZeneca France, Chiesi France, Lungpacer Inc., OSO-AI, TEVA France and Vitalaire. In addition, T. Similowski has a patent titled "brain-ventilator interface" licensed to My Brain Technologies, a patent for a "protection device for intubation", and a patent for a "non-contact thoracic movement imaging system".
Jodie L. Simpson has no potential conflicts of interest to disclose.
Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona.
Joan B. Soriano has received pharmaceutical company grants from Linde via Hospital Universitario de La Princesa; received consulting fees from ERS and SEPAR; and participated in speaking activities, advisory committees and consultancies for Air Liquide, Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, ERS, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, SEPAR and Takeda.
Daiana Stolz has received research grants from the Swiss National Foundation, AstraZeneca AG, Pan Gas AG, Weinmann AG, Curetis AG, Boston Scientific AG, Circassia Pharmaceuticals and Lungenliga Switzerland; received payment for lectures, advisory panels or sponsorship to attend scientific meetings from Novartis AG, AstraZeneca AG, GSK AG, Roche AG, Zambon, Pfizer and Schwabe Pharma AG. D. Stolz is the current education council chair of the European Respiratory Society and immediate past president of the European Board of Accreditation in Pneumology, and is the current GOLD representative for Switzerland.
Louise V. Wain has received research funding or financial support from Pfizer, GSK, Orion Pharma and Genentech, and undertaken consultancy for Galapagos and BI.
Simon L.F. Walsh has received personal fees from Boehringer-Ingelheim (for steering committee membership and for lecturing), and personal fees from Sanofi-Genzyme and Roche (for consultancy work).
Jason Weatherald has received research grants paid to his institution from the Canadian Institutes for Health Research, Heart and Stroke Foundation of Canada, Janssen, Actelion, Merck and Bayer; consulting fees paid personally from Janssen; honoraria for lectures from Janssen; payment for expert testimony from Sprigings Intellectual Property Law; travel support from Janssen; and payment for participation in advisory boards from Janssen and Acceleron.
Tobias Welte has received personal fees for lectures and participating on advisory boards from CSL Behring, Biotest, Boehringer, AstraZeneca, Novartis, GSK, Bayer, Pfizer and Grifols; and has received research funding and participated in clinical trials as a principal investigator for Boehringer, GSK, Novartis, Roche, Zambon and AstraZeneca.
Marlies Wijsenbeek has received research funding from Boehringer Ingelheim, Hoffman la Roche, The Netherlands Organization for Health Research and Development (ZonMw), The Dutch Lung Foundation (Longfonds), The Dutch PulmonologistSociety (NVATL), The Dutch Pulmonary Fibrosis Patients Association, The Sarcoidosis Patient Association, The Thorax Foundation and Erasmus MC; and speaker and/or consultancy fees from Boehringer Ingelheim, Hoffman la Roche, Galapagos, Galecto, Respivant, BMS, Novartis, Puretech, Savara and NeRRe therapeutics. All grants and fees were paid to her institution.
Roham Zamanian has no potential conflicts of interest to disclose.
Page last updated in April 2021